Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,962 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators. Steg PG, et al. Among authors: lip gy. Eur Heart J. 2011 Oct;32(20):2541-54. doi: 10.1093/eurheartj/ehr334. Epub 2011 Aug 30. Eur Heart J. 2011. PMID: 21878434 Free PMC article. Clinical Trial.
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Van de Werf F, et al. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12. Eur Heart J. 2008. PMID: 19004841 No abstract available.
Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation.
Ruiz-Nodar JM, Marín F, Sánchez-Payá J, Hurtado JA, Valencia-Martín J, Manzano-Fernández S, Roldán V, Pérez-Andreu V, Sogorb F, Valdés M, Lip GY. Ruiz-Nodar JM, et al. Among authors: lip gy. Eur Heart J. 2009 Apr;30(8):932-9. doi: 10.1093/eurheartj/ehp045. Epub 2009 Feb 26. Eur Heart J. 2009. PMID: 19246502
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF; Steering Committee. Lip GY, et al. Eur Heart J. 2009 Dec;30(23):2897-907. doi: 10.1093/eurheartj/ehp318. Epub 2009 Aug 18. Eur Heart J. 2009. PMID: 19690349 Free PMC article. Clinical Trial.
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F; Consensus Document of European Society of Cardiology Working Group on Thrombosis. Lip GY, et al. Eur Heart J. 2010 Jun;31(11):1311-8. doi: 10.1093/eurheartj/ehq117. Epub 2010 May 6. Eur Heart J. 2010. PMID: 20447945
3,962 results